Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TYMS | P04818 | 6/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6512236 | 0.90 | TYMS (0.47) | KDM4EHPGDALDH1A1TYMSCA1 | |
| SCHEMBL6509794 | 0.89 | KDM4E (0.40) | KDM4EHPGDALDH1A1TYMSCA1 | |
| SCHEMBL6509910 | 0.89 | KDM4E (0.40) | KDM4EHPGDALDH1A1TYMSCA1 | |
| SCHEMBL6510663 | 0.85 | KDM4E (0.47) | KDM4EHPGDTYMSCA1CA2 | |
| SCHEMBL6509682 | 0.81 | KDM4E (0.48) | KDM4EHPGDALDH1A1CA1CA2 | |
| SCHEMBL2638767 | 0.78 | TYMS (0.53) | KDM4EHPGDTYMSCA1CA2 | |
| SCHEMBL28905229 | 0.78 | TYMS (0.53) | KDM4EHPGDTYMSCA1CA2 | |
| SCHEMBL6512041 | 0.76 | CA2 (0.47) | KDM4EHPGDTYMSCA1CA2 | |
| SCHEMBL7609045 | 0.75 | NAALAD2 (0.47) | CA1CA2CA12CA9FOLH1 | |
| SCHEMBL7258566 | 0.75 | NAALAD2 (0.47) | CA1CA2CA12CA9FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1165493-A1 | NITROGEN MUSTARD COMPOUNDS AND PRODRUGS THEREFOR | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2002-01-02 | — | — | EP | claimed |
| WO-2000058271-A1 | NITROGEN MUSTARD COMPOUNDS AND PRODRUGS THEREFOR | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-10-05 | — | — | WO | claimed |
| US-6852755-B1 | Nitrogen mustard compounds and prodrugs therefor | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2005-02-08 | — | — | US | disclosed |
| EP-1165493-B1 | NITROGEN MUSTARD COMPOUNDS AND PRODRUGS THEREFOR | CANCER REC TECH LTD (GB) | 2005-01-19 | — | — | EP | disclosed |
| US-20040014187-A1 | Bacterial carboxypeptidase cpg2 variants and their use in gene directed enzyme prodrug therapy | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2004-01-22 | — | — | US | disclosed |
| EP-1280921-A1 | BACTERIAL CARBOXYPEPTIDASE CPG2 VARIANTS AND THEIR USE IN GENE DIRECTED ENZYME PRODRUG THERAPY | Cancer Research Ventures Limited (GB) | 2003-02-05 | — | — | EP | disclosed |
| EP-1165493-A1 | NITROGEN MUSTARD COMPOUNDS AND PRODRUGS THEREFOR | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001085960-A1 | BACTERIAL CARBOXYPEPTIDASE CPG2 VARIANTS AND THEIR USE IN GENE DIRECTED ENZYME PRODRUG THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| WO-2000058271-A1 | NITROGEN MUSTARD COMPOUNDS AND PRODRUGS THEREFOR | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-10-05 | — | — | WO | disclosed |